D'Arcangelis Alexandra, Goswami Chatterjee Sayantani, Diaz Isabel, Guehenneux Sabine, Namkoong Jin, Wu Joanna
Skin Research and Innovation, Global Personal Care and Skin Health R&D, Colgate-Palmolive Company, Piscataway, New Jersey, USA.
Dermal Clinical Research, Colgate-Palmolive Company, Piscataway, New Jersey, USA.
Int J Cosmet Sci. 2025 Feb;47(1):18-30. doi: 10.1111/ics.12987. Epub 2024 Aug 9.
Periorbital skin ageing signs are multidimensional, highly visible and a concern for many. We evaluated the potential efficacy of an eye cream to diminish these signs.
Biological markers associated with ageing, barrier function and homeostasis were analysed in vitro to determine the effects of topically applied eye cream, compared to those of a placebo using human skin tissue models and/or explants. Collagen IV, elastin and bone morphogenic protein 4 (BMP4) expression was investigated by immunohistochemical labelling, while filaggrin, kallikrein 7 (KLK7) and HB-EGF were evaluated by RT-qPCR. IL-1α and melanin levels in darkly pigmented skin models were also quantified. The protective effect of the cream on glycation was assessed by a non-enzymatic assay. Finally, the benefits of twice-daily applications of the eye cream for 56 days were instrumentally and clinically evaluated on 33 women.
Only the eye cream, not the placebo, stimulated collagen IV and BMP4 protein expression, as well as increased elastin fibre length. It also led to higher HB-EGF, filaggrin and KLK7 mRNA levels. The placebo and the eye cream did not induce changes in IL-1α and melanin levels, but both reduced non-enzymatic glycation. When assessing the in vivo effects of the cream, short-term results indicated skin hydration, transepidermal water loss (TEWL) and skin profilometry improvement within 15 min. Instrumental evaluations of wrinkles showed a reduction after 7 days, which was clinically perceivable after 28 or 56 days. The eye-opening angle and eyelid sagging also improved after seven and 28 days, respectively. Finally, dark circles became lighter within 7 days (instrumental measurement) or 28 days (clinical assessment).
The instrumental and clinical evaluations revealed that the eye cream reduced all periorbital ageing signs evaluated. Its effects are supported by the in vitro and ex vivo analyses of molecular markers.
眶周皮肤衰老迹象具有多维度性,非常明显,且为许多人所关注。我们评估了一款眼霜减轻这些迹象的潜在功效。
使用人体皮肤组织模型和/或外植体,在体外分析与衰老、屏障功能和内稳态相关的生物标志物,以确定局部应用眼霜与安慰剂相比的效果。通过免疫组织化学标记研究IV型胶原蛋白、弹性蛋白和骨形态发生蛋白4(BMP4)的表达,同时通过RT-qPCR评估丝聚蛋白、激肽释放酶7(KLK7)和HB-EGF。还对色素沉着较深的皮肤模型中的IL-1α和黑色素水平进行了定量。通过非酶法测定评估该面霜对糖基化的保护作用。最后,对33名女性进行了为期56天、每天两次使用该眼霜的效果的仪器测量评估和临床评估。
只有眼霜,而非安慰剂,刺激了IV型胶原蛋白和BMP4蛋白的表达,同时增加了弹性纤维长度。它还导致更高的HB-EGF、丝聚蛋白和KLK7 mRNA水平。安慰剂和眼霜均未引起IL-1α和黑色素水平的变化,但两者均降低了非酶糖基化作用。在评估该面霜的体内效果时,短期结果表明在15分钟内皮肤水合作用、经表皮水分流失(TEWL)和皮肤轮廓测量得到改善。对皱纹的仪器测量评估显示7天后有所减少,28天或56天后在临床上可察觉到。睁眼角度和眼睑下垂也分别在7天和28天后得到改善。最后,黑眼圈在7天(仪器测量)或28天(临床评估)内变浅。
仪器测量评估和临床评估表明,该眼霜减少了所评估的所有眶周衰老迹象。其效果得到了分子标志物的体外和离体分析的支持。